EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of TLR7 Genetic Variants rs179008 and rs3853839 on Susceptibility to Severe Coronavirus Disease 2019

Maryam Noroozi iD, Gholamreza Daryabor iD, Reza Shafiei iD, Mona Fani iD, Seppo Meri iD, Kurosh Kalantar iD

Immunity, Inflammation and Disease · 2026-11 · 14 (11)

DOI: 10.1002/iid3.70585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 13.11.2026. Verfasst von Maryam Noroozi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Polymorphism, Single Nucleotide, Genetic Predisposition to Disease, Pneumonia, Viral. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shiraz University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Coronavirus disease 2019 (COVID‐19) exhibits a broad clinical spectrum, ranging from asymptomatic infection to severe pneumonia and respiratory failure. Accumulating evidence indicates that host genetic variations, particularly those governing innate immune responses and type I interferon (IFN‑I) production, critically dictate disease trajectories. Toll‐like receptor 7 (TLR7), an X‐linked sensor that recognizes single‐stranded RNA viruses, is a fundamental initiator of antiviral IFN‐I responses. Hence, functional polymorphisms within the TLR7 gene may substantially alter individual susceptibility to severe COVID‐19.

Objective

This hospital‐based case‐control study aimed to evaluate the association of two TLR7 single‐nucleotide polymorphisms (SNPs), rs179008 and rs3853839, with COVID‐19 severity, with particular attention to sex‐specific effects given the X‐chromosomal location of the gene.

Methods

A total of 377 confirmed COVID‐19 patients, stratified into severe ( n = 182) and mild ( n = 195) groups, were matched for age and sex. Genotyping was performed using polymerase chain reaction–restriction fragment length polymorphism (PCR‐RFLP). All statistical analyses were rigorously stratified by sex to account for the X‐linked inheritance pattern of TLR7.

Results

For rs179008, the T allele exhibited a protective trend in both females (OR = 0.57, p = 0.085) and males (OR = 0.61, p = 0.213). Importantly, the TT genotype was absent in severe female cases but present in 8.2% of mild female cases, indicating a significant protective effect ( p = 0.029). Notably, pooling both sexes revealed a significant overall protective association for the T allele (overall frequency 13.4% in severe vs. 20.8% in mild; crude OR = 0.59, 95% CI: 0.37–0.95, p = 0.029). In the case of rs3853839, a strong association was observed in females; the heterozygous CG genotype was associated with a 2.2‐fold increased risk of severe disease compared to CC homozygotes (OR = 2.20, 95% CI: 1.13–4.29, p = 0.019), while a recessive model supported a protective effect of the CC genotype (OR = 0.50, 95% CI: 0.26–0.94, p = 0.032). In the combined allele analysis across both sexes, the G allele was significantly overrepresented in severe cases (30.8% vs. 23.0%; crude OR = 1.49, 95% CI: 1.01–2.19, p = 0.043), confirming a global risk effect consistent with the sex‑specific trends.

Conclusions

Our findings demonstrate that TLR7 polymorphisms rs179008 and rs3853839 are significantly associated with COVID‐19 severity, with distinct sex‐specific effects. The T allele of rs179008 confers protection, while the G allele of rs3853839 increases disease risk. These results underscore the importance of sex‐stratified genetic analyses and suggest that TLR7 variants may serve as potential biomarkers for risk stratification in COVID‐19 patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 7Polymorphism, Single NucleotideGenetic Predisposition to DiseasePneumonia, ViralBetacoronavirusCoronavirus InfectionsHumansFemaleMaleCOVID-19Case-Control StudiesSARS-CoV-2Middle AgedSeverity of Illness IndexAgedPandemicsGenotypeSex FactorsAdult

Stichwörter der Autor:innen

Toll‐like receptor 7 (TLR7)coronavirus disease 2019 (COVID‐19)severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)single‐nucleotide polymorphisms (SNPs)

Substanzen

Toll-Like Receptor 7TLR7 protein, human

Autor:innen und Institutionen

  • Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Vector-Borne Diseases Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Helsinki University Hospital, The University of Helsinki and HUSLAB, Helsinki, Finland.

ORCID-Profile: Maryam Noroozi, Gholamreza Daryabor, Reza Shafiei, Mona Fani, Seppo Meri, Kurosh Kalantar

Förderung

  • Shiraz University of Medical Sciences

Zitieren

APA

Noroozi, M., Daryabor, G., Shafiei, R., Fani, M., Meri, S., & Kalantar, K. (2026). Impact of TLR7 Genetic Variants rs179008 and rs3853839 on Susceptibility to Severe Coronavirus Disease 2019. Immunity, Inflammation and Disease, 14(11). https://doi.org/10.1002/iid3.70585

Vancouver

Noroozi M, Daryabor G, Shafiei R, Fani M, Meri S, Kalantar K. Impact of TLR7 Genetic Variants rs179008 and rs3853839 on Susceptibility to Severe Coronavirus Disease 2019. Immunity, Inflammation and Disease. 2026;14(11). doi:10.1002/iid3.70585

BibTeX
@article{Noroozi2026,
  author = {Noroozi, Maryam and Daryabor, Gholamreza and Shafiei, Reza and Fani, Mona and Meri, Seppo and Kalantar, Kurosh},
  title = {Impact of TLR7 Genetic Variants rs179008 and rs3853839 on Susceptibility to Severe Coronavirus Disease 2019},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  volume = {14},
  number = {11},
  doi = {10.1002/iid3.70585}
}
Kostenlos starten →